Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non-Current Assets: 2021-2024

Historic Non-Current Assets for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $4.2 million.

  • Amylyx Pharmaceuticals' Non-Current Assets rose 71.71% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year increase of 71.71%. This contributed to the annual value of $4.2 million for FY2024, which is 92.04% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Non-Current Assets of $4.2 million as of FY2024, which was down 92.04% from $52.8 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Non-Current Assets registered a high of $52.8 million during FY2023, and its lowest value of $663,000 during FY2021.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Non-Current Assets value was $9.3 million (recorded in 2022), while the average stood at $22.1 million.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Non-Current Assets surged by 1,305.73% in 2022, and later plummeted by 92.04% in 2024.
  • Amylyx Pharmaceuticals' Non-Current Assets (Yearly) stood at $663,000 in 2021, then surged by 1,305.73% to $9.3 million in 2022, then spiked by 466.39% to $52.8 million in 2023, then slumped by 92.04% to $4.2 million in 2024.